Skip to main content
رجوع
ZBIO logo

Zenas BioPharma, Inc.

جودة البيانات: 100%
ZBIO
NASDAQ Healthcare Biotechnology
KWD 20.63
▼ KWD 1.67 (-7.49%)
القيمة السوقية: 920.98M
نطاق اليوم
KWD 19.76 KWD 22.79
نطاق 52 أسبوعًا
KWD 6.11 KWD 44.60
حجم التداول
1,792,749
متوسط 50 يوم / 200 يوم
KWD 22.89 / KWD 22.80
الإغلاق السابق
KWD 22.30

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -2.4 0.4
P/B 3.8 2.9
ROE % -136.2 3.8
Net Margin % -3777.4 3.9
Rev Growth 5Y % 10.0
D/E 0.3 0.2

السعر المستهدف للمحللين

Hold
KWD 37.000 +79.4%
Low: KWD 19.000 High: KWD 48.000
ربحية السهم المستقبلية
-KWD 4.826
الإيرادات المقدّرة
9.4 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 -KWD 0.930
-KWD 1.307 – -KWD 0.360
510 M 1
FY2029 -KWD 2.678
-KWD 3.762 – -KWD 1.037
310 M 1
FY2028 -KWD 3.835
-KWD 4.933 – -KWD 2.041
160 M 5

النقاط الرئيسية

Debt/Equity of 0.33 — conservative balance sheet
Negative free cash flow of -172.35M
Capital efficient — spends only 0.18% of revenue on capex

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)100.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-136.22%
ROIC-49.22%
Net Margin-3777.37%
Op. Margin-2113.85%

الأمان

Debt / Equity
0.33
Current Ratio5.61
Interest Coverage0.00

التقييم

P/E Ratio
-2.44
P/B Ratio3.80
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 100.00% Revenue Growth (3Y) -55.28%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 10.00M Net Income (TTM) -377.74M
ROE -136.22% ROA -98.46%
Gross Margin 99.44% Operating Margin -2113.85%
Net Margin -3777.37% Free Cash Flow (TTM) -172.35M
ROIC -49.22% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.33 Current Ratio 5.61
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -2.44 P/B Ratio 3.80
P/S Ratio 92.10 PEG Ratio -0.03
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 920.98M Enterprise Value 890.30M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Revenue 10.00M 5.00M 50.00M 0.0
Net Income -377.74M -156.99M -37.12M -119.28M
EPS (Diluted) -8.44 -3.76 -0.97 -3.11
Gross Profit 9.94M -134.14M 50.00M -61.69M
Operating Income -211.39M -163.89M -37.15M -76.20M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Total Assets 383.64M 369.97M 68.18M 74.58M
Total Liabilities 141.50M 57.51M 293.90M 266.87M
Shareholders' Equity 242.14M 312.46M -225.72M -192.29M
Total Debt 79.96M 1.00M 21.11M 1.53M
Cash & Equivalents 110.64M 319.74M 56.86M 67.21M
Current Assets 351.17M 355.92M 59.80M 68.44M
Current Liabilities 62.65M 57.29M 23.26M 25.97M